Prior authorization list for advanced imaging/radiology CPT/HCPCS codes
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Oklahoma policy alerts
Know when Blue Cross Blue Shield - Oklahoma releases new policies or updates existing guidance.
Monitor payer policy activity
Lists CPT and HCPCS procedure codes for advanced imaging, molecular genetic, and select procedural services that may require prior authorization; identifies Carelon as the utilization manager for many listed codes and notes addition of site-of-care to medical necessity criteria effective 01/01/2025.
Addition of site of care to the medical necessity criteria for numerous advanced imaging/radiology codes effective 01/01/2025.
Effective 01/01/2025, addition of site of care to the medical necessity criteria for multiple advanced imaging CPT codes.
Multiple new molecular genetic test HCPCS U-codes (e.g., 0554U, 0555U, J0560U, 0561U, 0562U, 0565U, etc.) are being added effective 10/01/2025.
Cytogenomic optical genome mapping code 81195 added effective 04/01/2025.
Multiple new molecular genetic and related lab codes (0487U–0544U, etc.) and musculoskeletal/spine codes (0627T–0630T, 20930–20939, 20974–20975, 22206–22210) are added with management assigned to Carelon and effective dates.
Coverage Criteria and Medical Necessity Updates
Code listings and management assignments
Code listings and management assignments — consolidated operational listing indicating which codes are managed and any update/retirement notes. Codes listed below are grouped by service area and reflect the management assignment (Carelon unless otherwise noted) and any effective updates or retirement dates present in source content. This is an operational code listing; refer to the managed-utilization program for specific prior authorization or medical necessity rules.
ANY of the following
- Advanced Imaging/Radiology codes (examples from listing): 70336; 70450; 70460; 70470; 70480; 70492; 70496; 70498; 70540; 70542; 70543; 70552; 70553; 70554; 70555; 71250; 73222; 73223; 73225; 73700; 73701; 73702; 74150; 74160; 74170; 74174; 74175; Managed By = Carelon; Updates: Effective 01/01/2025 addition of site-of-care to medical necessity criteria (where indicated).
- Molecular Genetic Lab Testing and related U-codes/T-codes (examples from listing): 0554U; 0555U; J0560U; 0561U; 0562U; 0565U; 81193; 81194; 81195 (added effective 04/01/2025); 81200–81295 range entries; 81410–81437 range entries (panels with minimum gene content specified, e.g., 81410 requires ≥9 genes; 81430 requires ≥60 genes); various molecular codes including 0078U (Retire Effective 07/01/2025), 0079U, 0087U, 0088U, 0089U, 0238U, 0239U, J0242U, 0244U, 0363U, 0364U, 0368U, 0378U, 0379U, 0380U (Retire Effective 04/01/2025), 0388U, 0389U, 0428U (Retire Effective 04/01/2025), 0433U, 0434U, 0437U, 0438U, 0453U, 0454U, 0456U (Retire Effective 04/01/2025), 0460U, 0461U, 0487U (Add effective 07/01/2025), 0488U (Add effective 07/01/2025), 0489U (Add effective 07/01/2025), 0493U (Add effective 07/01/2025), 0627T–0630T (Add effective 10/01/2025), 0627T–0630T managed by Carelon; Managed By = Carelon except where blank in source; Updates: various add/retire dates as noted.
- Operational notes: where source indicates 'Managed By = Carelon' the code is subject to Carelon-managed utilization management and may require prior authorization or meet medical necessity criteria managed by Carelon. Several codes include explicit retirement effective dates (e.g., 0078U retire 07/01/2025; 0380U retire 04/01/2025; 0428U retire 04/01/2025; codes noted to retire 04/01/2025 within the 81433/81436/related entries). Some panel codes specify minimum gene content required for coverage (e.g., 81410, 81430, 81432, 81434, 81435, 81437).
Procedure and Test Code Listings
| 78582 | Pulmonary Ventilation (Eg Aerosol Or Gas) And Perfusion Imaging. |
| 78597 | Quantitative Differential Pulmonary Perfusion Including Imaging When Performed. |
| 78598 | Quantitative Differential Pulmonary Perfusion And Ventilation (Eg Aerosol Or Gas) Including Imaging When Performed. |
| 78600 | Brain Imaging Less Than 4 Static Views. |
| 78601 | Brain Imaging Less Than 4 Static Views; With Vascular Flow. |
| 78605 | Brain Imaging Minimum 4 Static Views. |
| 78606 | Brain Imaging Minimum 4 Static Views; With Vascular Flow. |
| 78608 | Brain Imaging Positron Emission Tomography (PET); Metabolic Evaluation. |
| 78609 | Brain Imaging Positron Emission Tomography (PET); Perfusion Evaluation. |
| 78610 | Brain Imaging Vascular Flow Only. |
What Providers Must Do
Obtain prior authorization when required
Services listed in this file are associated with CPT/HCPCS codes for which prior authorization may be required as of January 1, 2025; providers must obtain prior authorization where required prior to rendering services.
Follow Carelon prior-auth process and document site-of-care
Prior authorization and utilization management for the listed CPT codes are managed by Carelon; medical necessity criteria were updated to add site-of-care effective 01/01/2025 — include site-of-care information in requests and follow Carelon processes.
Submit authorization to assigned manager
Listed procedure, supply and molecular/genetic codes are assigned to a manager (Carelon or BCBSOK); submit prior authorization requests to the manager shown for each code and obtain approval before service.
Obtain Carelon authorization for Carelon-managed molecular tests
The HCPCS U‑codes and molecular test entries identified as 'Managed By = Carelon' require prior authorization per Carelon's utilization management process; providers must follow Carelon's authorization procedures when ordering these molecular tests.
Route prior-authorization requests to Carelon
Many CPT codes in the list are marked 'Managed By = Carelon' — prior authorization or utilization management requests for those CPT codes should be routed to Carelon.
Carelon prior authorization for CPT 81307–81405
The molecular genetic CPT codes in the 81307–81405 range are designated 'Managed By = Carelon' and are subject to the payer's utilization management — obtain prior authorization from Carelon for these molecular genetics procedures.
Carelon manages prior authorization for listed surgical/procedural CPTs
Surgical and procedural CPT codes listed under musculoskeletal/spine categories (examples in the document) are managed by Carelon; prior authorization is required through Carelon per the management assignment.
CPT 27412 requires Carelon prior authorization
Certain individual CPTs explicitly require prior authorization through Carelon; for example, CPT 27412 (Autologous Chondrocyte Implantation Knee) requires prior authorization through Carelon.
Reference manager-specific (Carelon) medical necessity criteria
Codes that list a managing organization include an 'Updates' note adding site-of-care to medical necessity; providers should reference the manager-specific (Carelon) medical necessity criteria when preparing authorization requests.
Reference exact procedure code and service category on requests
Claims and authorization submissions must reference the exact procedure code and service category as listed in the document to ensure routing to the correct manager and proper review.
Document specific molecular CPT or U‑code and follow Carelon UM
When submitting authorization or claims for molecular tests or U‑codes, document the specific CPT or U‑code being ordered and follow Carelon's utilization management documentation requirements for that code.
Use correct code effective dates and follow Carelon management
Submit claims and prior-authorization requests using the correct code effective date; many new U‑codes and T‑codes have specific add/effective dates (e.g., U‑codes effective 10/01/2025, 81195 effective 04/01/2025) and are managed by Carelon.
Prior Authorization and Utilization Management
Obtain authorization for advanced imaging effective 01/01/2025
Effective 01/01/2025, prior authorization may be required for advanced imaging (CT, MRI, CTA, MRA) codes listed in this document; specific authorization requirements and site-of-care considerations are determined by Carelon.
Carelon-managed advanced imaging — follow Carelon UM
Advanced imaging CPTs in the list are managed by Carelon; prior authorization and utilization management apply per Carelon processes and the updated site-of-care medical necessity criteria.
Obtain Carelon authorization for listed molecular genetic U‑codes
The listed molecular genetic U‑codes and PLA codes are managed by Carelon; providers must obtain authorization/management through Carelon when ordering these lab-based molecular genetic tests.
Carelon-managed molecular genetic CPTs require authorization
All listed CPT molecular genetic test codes (CPT 81307–81405) and related entries are managed by Carelon; obtain prior authorization and follow Carelon's utilization management procedures for these laboratory services.
Carelon manages 0627T–0630T (effective 10/01/2025) — obtain authorization
Interventional spine codes 0627T–0630T for percutaneous allogeneic disc injection are managed by Carelon with an add-effective date of 10/01/2025; follow Carelon authorization processes when these services are billed on or after that date.
Route surgical/procedural prior-auth to Carelon
Surgical and procedural CPT-coded interventions listed in the document are routed to Carelon for utilization management; submit prior authorization to Carelon as indicated for the specific procedure codes.
Follow Carelon UM for molecular/genetic lab testing
The molecular/genetic lab testing entries and U‑codes in this document are designated 'Managed By = Carelon'; providers must follow Carelon's utilization management and prior-authorization processes for those tests.
Contrast and Sequence Coding Notes
Code according to performed contrast sequence
Many CPT codes are provided in 'with' and 'without' contrast variants (or 'without followed by with'); code and bill according to the sequences actually performed and use the contrast-specific CPT variant when appropriate.
Select contrast-specific CPT code that matches performed sequences
Where CPT descriptors include 'without contrast', 'with contrast', or 'without followed by with contrast', select the correct CPT code that matches the contrast sequences performed for the study.
Report echocardiographic contrast (CPT 93352) separately and follow Carelon
Use of an echocardiographic contrast agent (CPT 93352) is listed as separately reportable and is managed by Carelon; submit authorization/documentation to the managing entity as required.
Definitions and Term Notes
Covered Indications (as stated in document extracts)
Imaging indications follow standard CPT descriptors; prior authorization and site-of-care considerations apply per managed criteria
Imaging indications correspond to the standard CPT descriptors; prior authorization and site-of-care considerations apply per the assigned manager's criteria
Detailed indication-level criteria are maintained by Carelon and are not reproduced in this document segment.
G0252 specified for PET imaging in diagnosis/surgical planning for breast cancer (initial staging of axillary lymph nodes)
G0252 is the CPT/HCPCS entry specified for PET imaging in breast cancer diagnosis and surgical planning
Managed By = Carelon; prior authorization/UM processes apply.
Cardiac imaging modalities listed without embedded clinical indication criteria in this fragment
Cardiac imaging modalities are listed; clinical indication criteria and prior authorization are managed externally
These entries are managed by Carelon for utilization review; providers should consult Carelon for indication-specific medical necessity rules.
Percutaneous injection of allogeneic cellular/tissue product into intervertebral disc (0627T–0630T) — listed as new services managed by Carelon effective 10/1/2025
New interventional spine codes for allogeneic disc injection are added with Carelon management effective 10/01/2025
Prior authorization/ utilization management expected through Carelon beginning on the effective date.
Frequency Limits and Related Notes
Not Covered / Exclusions
The inventory identifies G0219 with the description "PET Imaging Whole Body; Melanoma For Non-Covered Indications". This labeling in the code list signals that there are non-covered indications associated with G0219, but the excerpt itself does not enumerate the specific non-covered clinical scenarios—those are defined elsewhere in payer or managed-vendor guidance.
Chunk 48 shows the G0252/G0219 area of the listing and specifically records G0219 as "PET Imaging Whole Body; Melanoma For Non-Covered Indications." The document therefore flags G0219 as relating to non-covered indications, but detailed exclusion wording or the exact non-covered scenarios are not provided in this excerpt.
Background and Scope
This policy section enumerates advanced imaging and related procedure codes across body regions and modalities that are subject to utilization management. The listing highlights that many entries are Managed By = Carelon and that administrative updates—most notably the addition of site-of-care to medical necessity criteria effective 01/01/2025—apply to the listed advanced imaging/radiology CPT and HCPCS codes.
Imaging entries use standard CPT descriptors for indications (e.g., CT head, MRI spine, PET) and include code-level variants for contrast sequencing. The document repeatedly notes that medical necessity criteria were updated to add site-of-care considerations effective 01/01/2025; however, this extract does not contain the full clinical appropriateness rules. Providers must follow the designated manager’s (Carelon) prior authorization and site-of-care policies when requesting authorization for the listed imaging services.
Policy Update History
Multiple new molecular genetic HCPCS U-codes (e.g., 0554U, 0555U, J0560U, 0561U, 0562U, 0565U) were added with effective date 10/01/2025 and are designated as managed by Carelon.
CPT code 81195 (cytogenomic optical genome mapping for hematologic malignancy) was added effective 04/01/2025 and is designated as managed by Carelon.
Addition of 'site of care' to the medical necessity criteria for numerous advanced imaging/radiology CPT codes, with the listed codes managed by Carelon, effective 01/01/2025.
Several new HCPCS/PLA U-codes (including 0554U, 0555U, J0560U, 0561U, 0562U, 0565U) were added effective 10/01/2025 and are managed by Carelon.
CPT 81195 (cytogenomic genome-wide analysis using optical genome mapping) was added effective 04/01/2025 and is managed by Carelon.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.